LGR4 CRISPR Activation Plasmid (h): sc-402643-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LGR4 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- LGR4 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by LGR4 CRISPR Activation Plasmid (h) and LGR4 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the LGR4 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LGR4 Antibody (C-12): sc-390630
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LGR4 CRISPR Activation Plasmid (h) | sc-402643-ACT | 20 µg | $397.00 | |||
LGR4 CRISPR Activation Plasmid (h2) | sc-402643-ACT-2 | 20 µg | $397.00 |
Human LGR4 (leucine-rich repeat–containing G protein-coupled receptor 4) is a membrane receptor that serves as a key modulator of R-spondin–potentiated Wnt/β-catenin signaling by influencing receptor complex stability at the cell surface. Through this axis, LGR4 helps regulate cellular proliferation, differentiation, and tissue homeostasis, with downstream effects on stem/progenitor cell behavior and epithelial remodeling. LGR4 activity intersects with pathways controlling cell fate decisions and morphogen-driven patterning, making it relevant to studies of developmental biology and regenerative processes. Dysregulated Wnt pathway inputs involving LGR4 have been associated with altered growth control and lineage specification in disease-related contexts.
LGR4 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous LGR4 expression without altering the underlying DNA sequence.
LGR4 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the LGR4 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the LGR4 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous LGR4 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native LGR4 locus and enabling the study of LGR4-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of LGR4 pathway restoration in tumor cells with silenced or reduced LGR4 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.